Emerging research suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may represent a promising advancement for weight loss . Initial patient trials have indicated considerable losses in abdominal mass , conceivably exceeding current body composition medications . Nevertheless , more study